Cantor Fitzgerald reiterates Rocket Lab stock rating on launch record By Investing.com

Cantor Fitzgerald reiterated an Overweight rating on Rocket Lab with an $85 price target, implying about 25% upside from the $68.05 share price. The company added a three-launch Electron contract with iQPS, bringing total missions for the customer to 15, while reporting 21 successful launches in fiscal 2025 and $601.8 million in trailing-12-month revenue, up 38%. Recent equity financing raised roughly $474 million in gross proceeds, supporting growth but also diluting the stock.

Analysis

RKLB is transitioning from a “story stock” to a financing-and-execution stock, which matters because the market will increasingly price the company on how efficiently it converts launch cadence into contracted backlog rather than on isolated mission wins. The new contract supports a higher-quality revenue mix, but the bigger signal is that repeat customers are sticking through the ramp, which reduces customer acquisition risk and should compress the probability of a demand gap in 2028-29. That said, the equity raise and forward sale structure also tell you dilution is still the primary bridge between today’s valuation and the future cash flow story.

The second-order dynamic is competitive: Rocket Lab’s improving launch reliability increases its credibility with institutional payload buyers who value schedule assurance over lowest price. That can pressure smaller launch peers that lack demonstrated cadence, while simultaneously reinforcing SpaceX’s moat at the very high end by making the market more bifurcated—trusted “second source” capacity on one side, dominant scale on the other. The most relevant near-term catalyst is not this contract but whether management can keep launch tempo high enough that each new award is seen as a leading indicator of operating leverage rather than a placeholder for further equity issuance.

The contrarian risk is that investors may be extrapolating contract announcements into a straight-line rerating before margin evidence appears. If capex, inventory, or launch prep costs rise faster than revenue, the market could punish RKLB as a “good growth, bad dilution” name over the next 1-2 quarters, especially if broader growth multiples compress. Longer term, the real upside only materializes if space services become a higher-margin layer that can absorb the fixed cost base; without that, the current enthusiasm can overshoot fundamentals.

Key Decisions for Investors

• Stay long RKLB only via pullbacks, not strength chasing: accumulate on 5-8% post-news weakness with a 3-6 month horizon; upside is a re-rate if cadence stays >20 launches/year, but downside is another capital raise/dilution overhang.
• For those already long RKLB, sell covered calls against a core position into volatility; the stock is likely to trade on headline beta until the market sees margin conversion, making premium capture attractive relative to upside in the next 1-2 quarters.
• Pair trade: long RKLB / short a lower-quality launch peer basket if available, or use RKLB vs. a diluted small-cap aerospace proxy; the edge is execution credibility and repeat customer retention, not just thematic exposure.
• If implied volatility spikes on contract headlines, consider a call spread rather than outright calls: the stock’s path dependency is high and dilution can cap upside, so defined-risk convexity is preferable.
• Avoid adding aggressively ahead of the next financing-related catalyst; if the market starts pricing in additional equity issuance, reassess with a lower entry target and wait for a fundamental checkpoint on backlog-to-revenue conversion.